 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > BioMedicines, Inc.
 |
BioMedicines, Inc. |
 |
 |
 |
PROFILE |
 |
BioMedicines sniffs out the competition for its drugs. The development-stage company identifies potential drug candidates in other firms' pipelines, then buys the rights to products it believes can be developed more efficiently or toward different indications. Lead drug candidate Biomed 77, acquired from Schering AG, is in clinical trials as a potential treatment for metastatic breast cancer. Its pipeline also includes omega interferon (purchased from Boehringer Ingelheim), which is being developed to treat hepatitis B and C; and Biomed 101 (from G.D. Searle), which may have applications for AIDS, melanoma, or kidney cancer. CEO Mark Moran founded the firm in 1997.
COMPETITION |
 |
Amgen Inc. (AMGN)
GMP Companies, Inc. (dossier)
Schering-Plough Corporation (SGP)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 0.40
Employees: 16
Revenue per employee: $25,000.00
KEY PEOPLE |
 |
Mark Moran
CEO
James M. Ahlers
CFO
CONTACT INFO |
 |
1301 Marina Village Pkwy., Ste. 200
Alameda, CA 94501
US
Phone: 510-814-0112
Fax: 510-814-0170
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |